Entos in Forbes AI50

“Our fourth annual AI 50 list, produced in partnership with Sequoia Capital, recognizes standouts in privately-held North American companies making the most interesting and effective use of artificial intelligence technology,” announced Forbes Magazine in its announcement of the selection.  Consideration of the Forbes AI 50 list was open to any company based in North America, and this year’s list was selected from over 400 entries.

‍

"The Entos AI-driven HT platform yields better drug molecules, faster. We have demonstrated the platform to accelerate drug development for urgent unmet need in oncology."

– Tom Miller, Ph.D., Entos Co-Founder and CEO

‍

“The Entos AI-driven HT platform yields better drug molecules, faster,” said Entos Co-Founder and Chief Executive Officer, Tom Miller, Ph.D. “We have demonstrated the platform to accelerate drug development for urgent unmet need in oncology.”  At the heart of the Entos AI-driven HT platform is the proprietary OrbNet technology, which provides unprecedented accuracy across multiple drug-development endpoints while requiring 100x fewer experiments for training data.

"Selection for the Forbes AI 50 list is a testimony to the extraordinary team of Entos scientists and engineers that are driving the innovation behind this differentiated small-molecule therapeutics platform."

- Fred Manby, Ph.D., Entos Co-Founder and CTO

About Entos

Founded in 2019 and headquartered in San Diego, California, Entos is disrupting drug discovery with its cutting-edge platform that uses AI-driven high-throughput experimentation to rapidly develop small-molecule therapeutics. The Entos team is comprised of renowned scientists and engineers with world-class expertise in machine learning, medicinal chemistry, high-throughput experimentation, and drug discovery. Learn more about Entos' industry-revolutionizing platform at www.entos.ai.

Media Contacts

TJ White

Sard Verbinnen & Co.

Entos-SVC@sardverb.comSAN DIEGO, CA – Entos, Inc., the creator of a cutting-edge platform combining AI-driven technology and high-throughput (HT) experimentation to design small-molecule oncology therapeutics, was selected by Forbes Magazine for its AI 50 list of groundbreaking companies working in artificial intelligence (AI).